Prof G Markets Novo Nordisk Tanks 30%, P&G Takes a Tariff Hit & SoFi’s Monster Second Quarter
180 snips
Jul 30, 2025 Novo Nordisk's shares took a nosedive after disappointing earnings, raising alarms about its competitiveness against Eli Lilly. Meanwhile, Procter & Gamble grapples with tariff-induced costs, prompting them to raise consumer prices. The discussion also highlights SoFi's remarkable growth, driven by increased membership and revenue in the digital banking space, showcasing its strong positioning in a challenging market. It's a rollercoaster of insights into the shifting landscape of healthcare and consumer markets!
AI Snips
Chapters
Transcript
Episode notes
Novo Nordisk Ignores Real Threat
- Novo Nordisk's big shares plunge is mainly due to its focus on copycat GLP-1 drugs, ignoring competition from Eli Lilly's superior product.
- Despite a resolved supply shortage, Novo Nordisk lost market leadership to Eli Lilly, which controls 60% of the US weight loss drug market.
Doctors Favor Eli Lilly's Drug
- Doctors prefer Eli Lilly's GLP-1 drug due to better weight loss and fewer side effects.
- Some UK doctors have completely switched from Novo Nordisk's drug to Eli Lilly's for weight loss treatments.
Price War Could Regain Share
- Novo Nordisk could improve market share by initiating a price war with Eli Lilly.
- However, price wars in branded pharma are rare, and Novo Nordisk has shown no inclination to lower prices yet.